BiotechTube

Cipralex + Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
49
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Social Anxiety Disorder

Conditions

Social Anxiety Disorder

Trial Timeline

Oct 1, 2008 → Aug 1, 2013

NCT ID
NCT00485888

About Cipralex + Placebo

Cipralex + Placebo is a phase 2 stage product being developed by Lundbeck for Social Anxiety Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00485888. Target conditions include Social Anxiety Disorder.

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00485888Phase 2Completed

Competing Products

20 competing products in Social Anxiety Disorder

See all competitors
ProductCompanyStageHype Score
LY686017 + paroxetine + placeboEli LillyPhase 2
52
atomoxetine + placeboEli LillyPhase 2/3
65
ONO-1110 + PlaceboOno PharmaceuticalPhase 2
52
Cariprazine + PlaceboAbbVieApproved
85
QuetiapineAstraZenecaApproved
85
quetiapineAstraZenecaPhase 3
77
quetiapineAstraZenecaPhase 2/3
65
Seroquel + Sugar PillAstraZenecaPhase 3
77
quetiapineAstraZenecaApproved
85
Pristiq + PlaceboPfizerApproved
84
Venlafaxine ERPfizerPhase 3
76
Ziprasidone + SertralinePfizerPhase 2
51
Sertraline + PlaceboPfizerApproved
84
NefazodoneBristol Myers SquibbApproved
84
EscitalopramLundbeckApproved
82
BHV-0223 + PlaceboBiohavenPhase 2/3
60
VQW-765 + PlaceboVanda PharmaceuticalsPhase 3
69
PH94BVistagen TherapeuticsPhase 3
69
Fasedienol Nasal Spray - Placebo Nasal Spray + Fasedienol Nasal Spray - Fasedienol Nasal Spray + Placebo Nasal Spray - Placebo Nasal SprayVistagen TherapeuticsPhase 2
44
PH94B Nasal Spray + Placebo Nasal SprayVistagen TherapeuticsPhase 3
69

Other Products from Lundbeck

VortioxetineApproved
82
memantine + memantine + placeboApproved
82
escitalopram + escitalopramApproved
82
BrexpiprazoleApproved
82
losartan (drug)Approved
82